Table 1 Patient characteristics and clinical findings
Total | Sarcoma | Benign | p-value (sar. vs. ben.) | ||||
|---|---|---|---|---|---|---|---|
Number of patients | 63 | (100%) | 15 | (23.8%) | 48 | (76.2%) | |
Age (yr) | 50.1 | (24–84) | 60.3 | (38–84) | 46.9 | (24–73) | <0.001* |
Tumor size (cm) | 10.9 | (3.0-23.0) | 10.5 | (4.9-17.0) | 11.0 | (3.0-23.0) | 0.684 |
Serum CA125 (U/mL) | 41.5 | (3–347) | 77.5 | (8–347) | 29.5 | (3–235) | 0.078 |
Serum LDH (U/L) | 224.0 | (121–941) | 340.3 | (134–941) | 187.7 | (121–255) | 0.020* |
RI | 0.39 | (0.17-0.83) | 0.42 | (0.23-0.83) | 0.39 | (0.17-0.70) | 0.432 |
Clinical findings | |||||||
Rapid growth of the uterine tumor | 17 | (27.0%) | 1 | (6.7%) | 16 | (33.3%) | 0.042* |
Abnormal vaginal bleeding | 14 | (22.2%) | 6 | (40.0%) | 8 | (16.7%) | 0.058 |
A palpable pelvic mass | 10 | (15.9%) | 3 | (20.0%) | 7 | (14.6%) | 0.616 |
Pointed out the uterine tumor | 9 | (14.3%) | 1 | (6.7%) | 8 | (16.7%) | 0.334 |
Lower abdominal pain | 6 | (9.5%) | 2 | (13.3%) | 4 | (8.3%) | 0.565 |
Hypermenorrhea | 5 | (7.9%) | 1 | (6.7%) | 4 | (8.3%) | 0.835 |
Cough | 1 | (1.6%) | 1 | (6.7%) | 0 | (0%) | 0.071 |
Frequent urination | 1 | (1.6%) | 0 | (0%) | 1 | (2.1%) | 0.573 |
Total | 63 | (100%) | 15 | (100%) | 48 | (100%) | |